Last reviewed · How we verify

Dabigatran Etexilate 150mg

Kafrelsheikh University · FDA-approved active Small molecule Quality 5/100

Dabigatran Etexilate 150mg is a Small molecule drug developed by Kafrelsheikh University. It is currently FDA-approved. Also known as: group A.

At a glance

Generic nameDabigatran Etexilate 150mg
Also known asgroup A
SponsorKafrelsheikh University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dabigatran Etexilate 150mg

What is Dabigatran Etexilate 150mg?

Dabigatran Etexilate 150mg is a Small molecule drug developed by Kafrelsheikh University.

Who makes Dabigatran Etexilate 150mg?

Dabigatran Etexilate 150mg is developed and marketed by Kafrelsheikh University (see full Kafrelsheikh University pipeline at /company/kafrelsheikh-university).

Is Dabigatran Etexilate 150mg also known as anything else?

Dabigatran Etexilate 150mg is also known as group A.

What development phase is Dabigatran Etexilate 150mg in?

Dabigatran Etexilate 150mg is FDA-approved (marketed).

Related